Structure–Activity Relationship of SPOP Inhibitors against Kidney Cancer
datasetposted on 27.04.2020, 15:34 by Ze Dong, Zhen Wang, Zhong-Qiang Guo, Shouzhe Gong, Tao Zhang, Jiang Liu, Cheng Luo, Hualiang Jiang, Cai-Guang Yang
Speckle-type POZ protein (SPOP) is overexpressed in the nucleus and misallocated in the cytoplasm in almost all the clear-cell renal cell carcinomas (ccRCCs), which leads to kidney tumorigenesis. Previously, we elucidated that the oncogenic SPOP-signaling pathway in ccRCC could be suppressed by 6b that inhibits SPOP-mediated protein interactions. Herein, we have established a structure–activity relationship for 6b analogues as SPOP inhibitors. Compound 6lc suppresses the viability and inhibits the colony formation of ccRCC cell lines driven by cytoplasmic SPOP, superior to 6b. Compound 6lc binds to the SPOP protein in vitro and disrupts SPOP binding to phosphatase-and-tensin homologue (PTEN) in HEK293T cells, which causes the observable phenomena: a decline in the ubiquitination of PTEN, elevated levels of both PTEN and dual-specificity phosphatase 7, and decreased levels of phosphorylated AKT and ERK when ccRCC cell lines are exposed to 6lc in a dose–response manner. Taken together, compound 6lc is a potent candidate against kidney tumorigenesis.